SPORE for Translational Approaches to Brain Cancer

SPORE 用于脑癌转化方法

基本信息

批准号：
9981687
负责人：
MACIEJ S LESNIAK
金额：
$ 218.5万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-17 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9981687
关键词：
Address Adult Animals Apoptosis Autophagocytosis Brain Brain Neoplasms Cells Clinical Clinical Trials Collaborations Combined Modality Therapy Complex Cytolysis Cytotoxic Chemotherapy Diagnosis Disease Faculty Genes Glioblastoma Goals Human Immunosuppression Immunotherapy Incidence Individual Intracranial Neoplasms Investigation Kynurenine Malignant - descriptor Malignant Glioma Malignant Neoplasms Malignant neoplasm of brain Mediator of activation protein Modeling Multicenter Studies Nanoconjugate Nature Neoplasms Newly Diagnosed Operative Surgical Procedures Organ Patient-Focused Outcomes Patients Primary Brain Neoplasms Production Public Health RNA Interference Radiation Radiation therapy Records Recurrence Research Research Personnel Research Project Grants Residual Tumors Rodent Science Small Interfering RNA Spherical Nucleic Acids Surgically-Created Resection Cavity TP53 gene Talents Therapeutic Time Tissues Treatment outcome Ursidae Family Viral Virus Work antitumor effect base experience humanized mouse immune checkpoint blockade improved improved outcome inhibitor/antagonist interdisciplinary approach member multidisciplinary nanoparticle nanotherapeutic neoplastic cell nerve stem cell novel novel therapeutics oncolytic virotherapy outcome forecast particle pre-clinical research preclinical study preservation programmed cell death protein 1 programs standard care standard of care statistics success survivorship temozolomide translational approach tumor

项目摘要

OVERVIEW: SUMMARY The overall objective of the Northwestern Brain Tumor SPORE is to improve outcomes for brain tumor patients. Statistics on brain tumor incidence indicate that more than 23,000 people will be diagnosed with a brain tumor in the U.S. in 2017, and approximately 17,000 will succumb to their disease. Of the various primary intracerebral neoplasms, glioblastoma (GBM) is the most common. GBM patients that receive standard-of-care treatment have a median survival of 15 months, and 5-year survival is extremely rare. Progress in developing better treatments for this lethal tumor has been disappointing. A major contributor to this lack of therapeutic improvement is the delicate nature of the organ in which this cancer occurs. There are significant limitations to how aggressively GBM patients can be treated surgically, and the efficacy of systemically administered therapies are often compromised due to limited access to the brain. To address the public health problem that is associated with glioblastoma, we have assembled a talented team of investigators with extensive backgrounds in brain tumor research and therapy. All members of this team have professional records indicating success in directing their own programs of research. Some 3+ years ago, these faculty initiated group interactions in order to bring a team science approach to bear upon the study and treatment of GBM, and for which a multidisciplinary approach is needed for achieving meaningful progress.

概述：总结西北脑肿瘤 SPORE 的总体目标是改善脑肿瘤的治疗结果患者。脑肿瘤发病率统计表明，超过23,000人将被诊断出患有脑肿瘤 2017 年，美国将有大约 17,000 人死于脑肿瘤。各种初级脑内肿瘤，胶质母细胞瘤（GBM）是最常见的。接受标准护理的 GBM 患者治疗的中位生存期为 15 个月，5 年生存期极为罕见。开发进展对于这种致命肿瘤的更好治疗方法一直令人失望。造成这种治疗缺乏的一个主要原因改善是发生这种癌症的器官的脆弱性质。有很大的限制 GBM 患者可以如何积极地接受手术治疗，以及全身治疗的效果由于进入大脑的途径有限，治疗常常会受到影响。为了解决公共卫生问题与胶质母细胞瘤有关，我们组建了一支才华横溢的研究团队，拥有广泛的研究经验具有脑肿瘤研究和治疗的背景。该团队所有成员均有专业记录表明他们在指导自己的研究计划方面取得了成功。大约三年多前，这些教师发起了小组互动，以便将团队科学方法应用于 GBM 的研究和治疗，为此需要采取多学科方法来取得有意义的进展。